Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV
Identifieur interne : 002385 ( Main/Exploration ); précédent : 002384; suivant : 002386Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV
Auteurs : Ye V. Liu [États-Unis] ; Michael J. Massare [États-Unis] ; Dale L. Barnard [États-Unis] ; Thomas Kort [États-Unis] ; Margret Nathan [États-Unis] ; LEI WANG [États-Unis] ; Gale Smith [États-Unis]Source :
- Vaccine [ 0264-410X ] ; 2011.
Descripteurs français
- KwdFr :
- Adjuvants immunologiques (administration et posologie), Analyse de survie, Animaux, Anticorps antiviraux (sang), Anticorps neutralisants (sang), Baculoviridae (génétique), Charge virale, Femelle, Glycoprotéine de spicule des coronavirus, Glycoprotéines membranaires (génétique), Glycoprotéines membranaires (immunologie), Glycoprotéines membranaires (métabolisme), Hydroxyde d'aluminium (administration et posologie), Maladies des rongeurs (), Modèles animaux de maladie humaine, Multimérisation de protéines, Poids du corps, Poumon (virologie), Protéines de l'enveloppe virale (génétique), Protéines de l'enveloppe virale (immunologie), Protéines de l'enveloppe virale (métabolisme), Protéines de la matrice virale (génétique), Protéines de la matrice virale (métabolisme), Protéines recombinantes (génétique), Protéines recombinantes (immunologie), Protéines recombinantes (métabolisme), Souris, Souris de lignée BALB C, Syndrome respiratoire aigu sévère (), Vaccins antiviraux (génétique), Vaccins antiviraux (immunologie), Vaccins à virosomes (génétique), Vaccins à virosomes (immunologie), Vecteurs génétiques, Virus du SRAS (génétique), Virus du SRAS (immunologie).
- MESH :
- administration et posologie : Adjuvants immunologiques, Hydroxyde d'aluminium.
- génétique : Baculoviridae, Glycoprotéines membranaires, Protéines de l'enveloppe virale, Protéines de la matrice virale, Protéines recombinantes, Vaccins antiviraux, Vaccins à virosomes, Virus du SRAS.
- immunologie : Glycoprotéines membranaires, Protéines de l'enveloppe virale, Protéines recombinantes, Vaccins antiviraux, Vaccins à virosomes, Virus du SRAS.
- métabolisme : Glycoprotéines membranaires, Protéines de l'enveloppe virale, Protéines de la matrice virale, Protéines recombinantes.
- sang : Anticorps antiviraux, Anticorps neutralisants.
- virologie : Poumon.
- Pascal (Inist)
- Analyse de survie, Animaux, Charge virale, Femelle, Glycoprotéine de spicule des coronavirus, Maladies des rongeurs, Modèles animaux de maladie humaine, Multimérisation de protéines, Poids du corps, Souris, Souris de lignée BALB C, Syndrome respiratoire aigu sévère, Vecteurs génétiques, Virus syndrome respiratoire aigu sévère, Influenzavirus, Souris, Baculoviridae, Glycoprotéine, Particule type viral, Poumon, Anticorps neutralisant, Syndrome respiratoire aigu sévère, Grippe.
English descriptors
- KwdEn :
- Adjuvants, Immunologic (administration & dosage), Aluminum Hydroxide (administration & dosage), Animals, Antibodies, Neutralizing (blood), Antibodies, Viral (blood), Baculoviridae, Baculoviridae (genetics), Body Weight, Disease Models, Animal, Female, Genetic Vectors, Glycoprotein, Influenza, Influenzavirus, Insecta, Lung, Lung (virology), Membrane Glycoproteins (genetics), Membrane Glycoproteins (immunology), Membrane Glycoproteins (metabolism), Mice, Mice, Inbred BALB C, Mouse, Neutralizing antibody, Protein Multimerization, Recombinant Proteins (genetics), Recombinant Proteins (immunology), Recombinant Proteins (metabolism), Rodent Diseases (prevention & control), SARS Virus (genetics), SARS Virus (immunology), Severe Acute Respiratory Syndrome (prevention & control), Severe acute respiratory syndrome, Severe acute respiratory syndrome virus, Spike Glycoprotein, Coronavirus, Survival Analysis, Vaccines, Virosome (genetics), Vaccines, Virosome (immunology), Viral Envelope Proteins (genetics), Viral Envelope Proteins (immunology), Viral Envelope Proteins (metabolism), Viral Load, Viral Matrix Proteins (genetics), Viral Matrix Proteins (metabolism), Viral Vaccines (genetics), Viral Vaccines (immunology), Virus like particle.
- MESH :
- chemical , administration & dosage : Adjuvants, Immunologic, Aluminum Hydroxide.
- chemical , blood : Antibodies, Neutralizing, Antibodies, Viral.
- genetics : Baculoviridae, Membrane Glycoproteins, Recombinant Proteins, SARS Virus, Vaccines, Virosome, Viral Envelope Proteins, Viral Matrix Proteins, Viral Vaccines.
- chemical , immunology : Membrane Glycoproteins, Recombinant Proteins, SARS Virus, Vaccines, Virosome, Viral Envelope Proteins, Viral Vaccines.
- chemical , metabolism : Membrane Glycoproteins, Recombinant Proteins, Viral Envelope Proteins, Viral Matrix Proteins.
- prevention & control : Rodent Diseases, Severe Acute Respiratory Syndrome.
- virology : Lung.
- Animals, Body Weight, Disease Models, Animal, Female, Genetic Vectors, Insecta, Mice, Mice, Inbred BALB C, Protein Multimerization, Spike Glycoprotein, Coronavirus, Survival Analysis, Viral Load.
Abstract
SARS-CoV was the cause of the global pandemic in 2003 that infected over 8000 people in 8 months. Vaccines against SARS are still not available. We developed a novel method to produce high levels of a recombinant SARS virus-like particles (VLPs) vaccine containing the SARS spike (S) protein and the influenza M1 protein using the baculovirus insect cell expression system. These chimeric SARS VLPs have a similar size and morphology to the wild type SARS-CoV. We tested the immunogenicity and protective efficacy of purified chimeric SARS VLPs and full length SARS S protein vaccines in a mouse lethal challenge model. The SARS VLP vaccine, containing 0.8 μg of SARS S protein, completely protected mice from death when administered intramuscular (IM) or intranasal (IN) routes in the absence of an adjuvant. Likewise, the SARS VLP vaccine, containing 4 μg of S protein without adjuvant, reduced lung virus titer to below detectable level, protected mice from weight loss, and elicited a high level of neutralizing antibodies against SARS-CoV. Sf9 cell-produced full length purified SARS S protein was also an effective vaccine against SARS-CoV but only when co-administered IM with aluminum hydroxide. SARS-CoV VLPs are highly immunogenic and induce neutralizing antibodies and provide protection against lethal challenge. Sf9 cell-based VLP vaccines are a potential tool to provide protection against novel pandemic agents.
Url:
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000093
- to stream PascalFrancis, to step Curation: 000895
- to stream PascalFrancis, to step Checkpoint: 000107
- to stream Main, to step Merge: 002414
- to stream Pmc, to step Corpus: 001536
- to stream Pmc, to step Curation: 001536
- to stream Pmc, to step Checkpoint: 000B63
- to stream PubMed, to step Corpus: 001496
- to stream PubMed, to step Curation: 001496
- to stream PubMed, to step Checkpoint: 001525
- to stream Ncbi, to step Merge: 002358
- to stream Ncbi, to step Curation: 002358
- to stream Ncbi, to step Checkpoint: 002358
- to stream Main, to step Merge: 002173
- to stream Main, to step Curation: 002385
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV</title><author><name sortKey="Liu, Ye V" sort="Liu, Ye V" uniqKey="Liu Y" first="Ye V." last="Liu">Ye V. Liu</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Novavax Inc., 9920 Belward Campus Drive</s1><s2>Rockville, MD 20850</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Massare, Michael J" sort="Massare, Michael J" uniqKey="Massare M" first="Michael J." last="Massare">Michael J. Massare</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Novavax Inc., 9920 Belward Campus Drive</s1><s2>Rockville, MD 20850</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Barnard, Dale L" sort="Barnard, Dale L" uniqKey="Barnard D" first="Dale L." last="Barnard">Dale L. Barnard</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Institute for Antiviral Research, Utah State University</s1><s2>Logan, UT 84322</s2><s3>USA</s3><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Utah</region></placeName></affiliation></author><author><name sortKey="Kort, Thomas" sort="Kort, Thomas" uniqKey="Kort T" first="Thomas" last="Kort">Thomas Kort</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Novavax Inc., 9920 Belward Campus Drive</s1><s2>Rockville, MD 20850</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Nathan, Margret" sort="Nathan, Margret" uniqKey="Nathan M" first="Margret" last="Nathan">Margret Nathan</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Novavax Inc., 9920 Belward Campus Drive</s1><s2>Rockville, MD 20850</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Lei Wang" sort="Lei Wang" uniqKey="Lei Wang" last="Lei Wang">LEI WANG</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Novavax Inc., 9920 Belward Campus Drive</s1><s2>Rockville, MD 20850</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Smith, Gale" sort="Smith, Gale" uniqKey="Smith G" first="Gale" last="Smith">Gale Smith</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Novavax Inc., 9920 Belward Campus Drive</s1><s2>Rockville, MD 20850</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">11-0394533</idno><date when="2011">2011</date><idno type="stanalyst">PASCAL 11-0394533 INIST</idno><idno type="RBID">Pascal:11-0394533</idno><idno type="wicri:Area/PascalFrancis/Corpus">000093</idno><idno type="wicri:Area/PascalFrancis/Curation">000895</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000107</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000107</idno><idno type="wicri:doubleKey">0264-410X:2011:Liu Y:chimeric:severe:acute</idno><idno type="wicri:Area/Main/Merge">002414</idno><idno type="wicri:source">PMC</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165014</idno><idno type="RBID">PMC:3165014</idno><idno type="wicri:Area/Pmc/Corpus">001536</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001536</idno><idno type="wicri:Area/Pmc/Curation">001536</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">001536</idno><idno type="wicri:Area/Pmc/Checkpoint">000B63</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000B63</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:21762752</idno><idno type="wicri:Area/PubMed/Corpus">001496</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001496</idno><idno type="wicri:Area/PubMed/Curation">001496</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001496</idno><idno type="wicri:Area/PubMed/Checkpoint">001525</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001525</idno><idno type="wicri:Area/Ncbi/Merge">002358</idno><idno type="wicri:Area/Ncbi/Curation">002358</idno><idno type="wicri:Area/Ncbi/Checkpoint">002358</idno><idno type="wicri:doubleKey">0264-410X:2011:Liu Y:chimeric:severe:acute</idno><idno type="wicri:Area/Main/Merge">002173</idno><idno type="wicri:Area/Main/Curation">002385</idno><idno type="wicri:Area/Main/Exploration">002385</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV</title><author><name sortKey="Liu, Ye V" sort="Liu, Ye V" uniqKey="Liu Y" first="Ye V." last="Liu">Ye V. Liu</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Novavax Inc., 9920 Belward Campus Drive</s1><s2>Rockville, MD 20850</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Massare, Michael J" sort="Massare, Michael J" uniqKey="Massare M" first="Michael J." last="Massare">Michael J. Massare</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Novavax Inc., 9920 Belward Campus Drive</s1><s2>Rockville, MD 20850</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Barnard, Dale L" sort="Barnard, Dale L" uniqKey="Barnard D" first="Dale L." last="Barnard">Dale L. Barnard</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Institute for Antiviral Research, Utah State University</s1><s2>Logan, UT 84322</s2><s3>USA</s3><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Utah</region></placeName></affiliation></author><author><name sortKey="Kort, Thomas" sort="Kort, Thomas" uniqKey="Kort T" first="Thomas" last="Kort">Thomas Kort</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Novavax Inc., 9920 Belward Campus Drive</s1><s2>Rockville, MD 20850</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Nathan, Margret" sort="Nathan, Margret" uniqKey="Nathan M" first="Margret" last="Nathan">Margret Nathan</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Novavax Inc., 9920 Belward Campus Drive</s1><s2>Rockville, MD 20850</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Lei Wang" sort="Lei Wang" uniqKey="Lei Wang" last="Lei Wang">LEI WANG</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Novavax Inc., 9920 Belward Campus Drive</s1><s2>Rockville, MD 20850</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Smith, Gale" sort="Smith, Gale" uniqKey="Smith G" first="Gale" last="Smith">Gale Smith</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Novavax Inc., 9920 Belward Campus Drive</s1><s2>Rockville, MD 20850</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author></analytic><series><title level="j" type="main">Vaccine</title><title level="j" type="abbreviated">Vaccine</title><idno type="ISSN">0264-410X</idno><imprint><date when="2011">2011</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Vaccine</title><title level="j" type="abbreviated">Vaccine</title><idno type="ISSN">0264-410X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic (administration & dosage)</term><term>Aluminum Hydroxide (administration & dosage)</term><term>Animals</term><term>Antibodies, Neutralizing (blood)</term><term>Antibodies, Viral (blood)</term><term>Baculoviridae</term><term>Baculoviridae (genetics)</term><term>Body Weight</term><term>Disease Models, Animal</term><term>Female</term><term>Genetic Vectors</term><term>Glycoprotein</term><term>Influenza</term><term>Influenzavirus</term><term>Insecta</term><term>Lung</term><term>Lung (virology)</term><term>Membrane Glycoproteins (genetics)</term><term>Membrane Glycoproteins (immunology)</term><term>Membrane Glycoproteins (metabolism)</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Mouse</term><term>Neutralizing antibody</term><term>Protein Multimerization</term><term>Recombinant Proteins (genetics)</term><term>Recombinant Proteins (immunology)</term><term>Recombinant Proteins (metabolism)</term><term>Rodent Diseases (prevention & control)</term><term>SARS Virus (genetics)</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (prevention & control)</term><term>Severe acute respiratory syndrome</term><term>Severe acute respiratory syndrome virus</term><term>Spike Glycoprotein, Coronavirus</term><term>Survival Analysis</term><term>Vaccines, Virosome (genetics)</term><term>Vaccines, Virosome (immunology)</term><term>Viral Envelope Proteins (genetics)</term><term>Viral Envelope Proteins (immunology)</term><term>Viral Envelope Proteins (metabolism)</term><term>Viral Load</term><term>Viral Matrix Proteins (genetics)</term><term>Viral Matrix Proteins (metabolism)</term><term>Viral Vaccines (genetics)</term><term>Viral Vaccines (immunology)</term><term>Virus like particle</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adjuvants immunologiques (administration et posologie)</term><term>Analyse de survie</term><term>Animaux</term><term>Anticorps antiviraux (sang)</term><term>Anticorps neutralisants (sang)</term><term>Baculoviridae (génétique)</term><term>Charge virale</term><term>Femelle</term><term>Glycoprotéine de spicule des coronavirus</term><term>Glycoprotéines membranaires (génétique)</term><term>Glycoprotéines membranaires (immunologie)</term><term>Glycoprotéines membranaires (métabolisme)</term><term>Hydroxyde d'aluminium (administration et posologie)</term><term>Maladies des rongeurs ()</term><term>Modèles animaux de maladie humaine</term><term>Multimérisation de protéines</term><term>Poids du corps</term><term>Poumon (virologie)</term><term>Protéines de l'enveloppe virale (génétique)</term><term>Protéines de l'enveloppe virale (immunologie)</term><term>Protéines de l'enveloppe virale (métabolisme)</term><term>Protéines de la matrice virale (génétique)</term><term>Protéines de la matrice virale (métabolisme)</term><term>Protéines recombinantes (génétique)</term><term>Protéines recombinantes (immunologie)</term><term>Protéines recombinantes (métabolisme)</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Syndrome respiratoire aigu sévère ()</term><term>Vaccins antiviraux (génétique)</term><term>Vaccins antiviraux (immunologie)</term><term>Vaccins à virosomes (génétique)</term><term>Vaccins à virosomes (immunologie)</term><term>Vecteurs génétiques</term><term>Virus du SRAS (génétique)</term><term>Virus du SRAS (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Adjuvants, Immunologic</term><term>Aluminum Hydroxide</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Neutralizing</term><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Adjuvants immunologiques</term><term>Hydroxyde d'aluminium</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Baculoviridae</term><term>Membrane Glycoproteins</term><term>Recombinant Proteins</term><term>SARS Virus</term><term>Vaccines, Virosome</term><term>Viral Envelope Proteins</term><term>Viral Matrix Proteins</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Baculoviridae</term><term>Glycoprotéines membranaires</term><term>Protéines de l'enveloppe virale</term><term>Protéines de la matrice virale</term><term>Protéines recombinantes</term><term>Vaccins antiviraux</term><term>Vaccins à virosomes</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Glycoprotéines membranaires</term><term>Protéines de l'enveloppe virale</term><term>Protéines recombinantes</term><term>Vaccins antiviraux</term><term>Vaccins à virosomes</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Membrane Glycoproteins</term><term>Recombinant Proteins</term><term>SARS Virus</term><term>Vaccines, Virosome</term><term>Viral Envelope Proteins</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Membrane Glycoproteins</term><term>Recombinant Proteins</term><term>Viral Envelope Proteins</term><term>Viral Matrix Proteins</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Glycoprotéines membranaires</term><term>Protéines de l'enveloppe virale</term><term>Protéines de la matrice virale</term><term>Protéines recombinantes</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Rodent Diseases</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term><term>Anticorps neutralisants</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Poumon</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Lung</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Body Weight</term><term>Disease Models, Animal</term><term>Female</term><term>Genetic Vectors</term><term>Insecta</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Protein Multimerization</term><term>Spike Glycoprotein, Coronavirus</term><term>Survival Analysis</term><term>Viral Load</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Analyse de survie</term><term>Animaux</term><term>Charge virale</term><term>Femelle</term><term>Glycoprotéine de spicule des coronavirus</term><term>Maladies des rongeurs</term><term>Modèles animaux de maladie humaine</term><term>Multimérisation de protéines</term><term>Poids du corps</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Syndrome respiratoire aigu sévère</term><term>Vecteurs génétiques</term><term>Virus syndrome respiratoire aigu sévère</term><term>Influenzavirus</term><term>Souris</term><term>Baculoviridae</term><term>Glycoprotéine</term><term>Particule type viral</term><term>Poumon</term><term>Anticorps neutralisant</term><term>Syndrome respiratoire aigu sévère</term><term>Grippe</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">SARS-CoV was the cause of the global pandemic in 2003 that infected over 8000 people in 8 months. Vaccines against SARS are still not available. We developed a novel method to produce high levels of a recombinant SARS virus-like particles (VLPs) vaccine containing the SARS spike (S) protein and the influenza M1 protein using the baculovirus insect cell expression system. These chimeric SARS VLPs have a similar size and morphology to the wild type SARS-CoV. We tested the immunogenicity and protective efficacy of purified chimeric SARS VLPs and full length SARS S protein vaccines in a mouse lethal challenge model. The SARS VLP vaccine, containing 0.8 μg of SARS S protein, completely protected mice from death when administered intramuscular (IM) or intranasal (IN) routes in the absence of an adjuvant. Likewise, the SARS VLP vaccine, containing 4 μg of S protein without adjuvant, reduced lung virus titer to below detectable level, protected mice from weight loss, and elicited a high level of neutralizing antibodies against SARS-CoV. Sf9 cell-produced full length purified SARS S protein was also an effective vaccine against SARS-CoV but only when co-administered IM with aluminum hydroxide. SARS-CoV VLPs are highly immunogenic and induce neutralizing antibodies and provide protection against lethal challenge. Sf9 cell-based VLP vaccines are a potential tool to provide protection against novel pandemic agents.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Maryland</li><li>Utah</li></region></list><tree><country name="États-Unis"><region name="Maryland"><name sortKey="Liu, Ye V" sort="Liu, Ye V" uniqKey="Liu Y" first="Ye V." last="Liu">Ye V. Liu</name></region><name sortKey="Barnard, Dale L" sort="Barnard, Dale L" uniqKey="Barnard D" first="Dale L." last="Barnard">Dale L. Barnard</name><name sortKey="Kort, Thomas" sort="Kort, Thomas" uniqKey="Kort T" first="Thomas" last="Kort">Thomas Kort</name><name sortKey="Lei Wang" sort="Lei Wang" uniqKey="Lei Wang" last="Lei Wang">LEI WANG</name><name sortKey="Massare, Michael J" sort="Massare, Michael J" uniqKey="Massare M" first="Michael J." last="Massare">Michael J. Massare</name><name sortKey="Nathan, Margret" sort="Nathan, Margret" uniqKey="Nathan M" first="Margret" last="Nathan">Margret Nathan</name><name sortKey="Smith, Gale" sort="Smith, Gale" uniqKey="Smith G" first="Gale" last="Smith">Gale Smith</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002385 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002385 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:11-0394533
|texte= Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV
}}
| This area was generated with Dilib version V0.6.33. |  |